This page provides a comprehensive overview of research hypotheses in neurodegenerative disease research, covering major mechanistic theories and emerging concepts that explain the pathogenesis of Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and related disorders. Understanding these hypotheses is critical for developing effective therapeutic interventions and biomarkers. [@selkoe2023]
| Hypothesis | Support Level | Key Evidence | Testability | Therapeutic Potential |
|---|---|---|---|---|
| Amyloid cascade | Strong | Genetic, biochemical, biomarker | 10/10 | 8/10 |
| Tau spreading | Strong | Animal models, human imaging | 10/10 | 8/10 |
| Neuroinflammation | Moderate-Strong | Genetics, imaging, CSF | 8/10 | 9/10 |
| Mitochondrial dysfunction | Moderate | Biochemical, genetic | 7/10 | 7/10 |
| Metabolic failure | Emerging | Genetics, imaging, PET | 7/10 | 8/10 |
| Network failure | Strong | fMRI, EEG, connectivity | 9/10 | 7/10 |
| Hypothesis | Support Level | Key Evidence | Testability | Therapeutic Potential |
|---|---|---|---|---|
| Alpha-synuclein aggregation | Strong | Genetic, pathological, biochemical | 10/10 | 9/10 |
| Mitochondrial dysfunction | Strong | Genetics, biochemical, iPSC | 9/10 | 9/10 |
| Neuroinflammation | Moderate-Strong | Imaging, genetics, CSF | 8/10 | 8/10 |
| Calcium dysregulation | Moderate | Electrophysiology, imaging | 7/10 | 7/10 |
| Metal dyshomeostasis | Limited | Biochemical | 6/10 | 6/10 |
| Vesicle trafficking | Moderate | Cell biology, genetics | 7/10 | 8/10 |
| Hypothesis | Support Level | Key Evidence | Testability | Therapeutic Potential |
|---|---|---|---|---|
| RNA metabolism | Strong | Genetics, pathology, biochemistry | 8/10 | 7/10 |
| Protein aggregation | Strong | Pathology, genetics | 9/10 | 8/10 |
| Mitochondrial dysfunction | Moderate | Biochemical, cell models | 7/10 | 7/10 |
| Neuroinflammation | Moderate-Strong | Imaging, genetics, CSF | 8/10 | 8/10 |
| Cytoskeletal defects | Moderate | Pathology, genetics | 7/10 | 6/10 |
The amyloid cascade hypothesis, first proposed by Hardy and Higgins in 1992, remains the dominant framework for understanding AD pathogenesis. [@Hardy1992] The hypothesis posits that accumulation of amyloid-beta (Aβ) peptides, particularly the Aβ42 isoform, is the primary initiating event that triggers a cascade of downstream pathologies including tau hyperphosphorylation, neuroinflammation, synaptic loss, and neuronal death.
Evidence Breakdown:
Confidence Level: Strong — Supported by multiple independent lines of evidence including genetics, biochemistry, imaging, and therapeutic response.
Testability Score: 10/10 — Easily testable via amyloid PET, CSF biomarkers, and anti-amyloid antibodies.
Therapeutic Potential Score: 8/10 — Anti-amyloid therapies have shown efficacy but disease modification requires combination approaches.
The tau spreading hypothesis, based on Braak staging, proposes that tau pathology spreads along neural circuits in a predictable pattern beginning in the entorhinal cortex and progressing to the hippocampus and neocortex. [@braak2003] This prion-like propagation model explains the pattern of memory impairment followed by cortical deficits in AD.
Evidence Breakdown:
Confidence Level: Strong — Extensive human and experimental evidence supports templated propagation of tau pathology.
Testability Score: 10/10 — Tau PET and fluid biomarkers allow direct visualization and measurement of tau pathology.
Therapeutic Potential Score: 8/10 — Anti-tau therapies in development; timing critical as interventions must occur before widespread spread.
The neuroinflammation hypothesis proposes that chronic activation of microglia and astrocytes drives neurodegeneration through pro-inflammatory cytokines, complement activation, and synaptic pruning. [@neuroinf2021] This hypothesis has gained substantial traction with the identification of genetic risk factors including TREM2 variants that impair microglial function.
Evidence Breakdown:
Confidence Level: Moderate-Strong — Strong genetic and imaging evidence but mechanisms remain incompletely characterized.
Testability Score: 8/10 — TSPO PET and cytokine measurements allow assessment of neuroinflammation status.
Therapeutic Potential Score: 9/10 — Microglial modulation represents a highly promising therapeutic strategy with multiple targets.
The α-synuclein aggregation hypothesis is the central mechanistic framework for PD pathogenesis. Alpha-synuclein is a presynaptic protein that can misfold into β-sheet-rich aggregates that form Lewy bodies and propagate throughout the nervous system. [@park2014]
Evidence Breakdown:
Confidence Level: Strong — Multiple independent evidence streams converge on α-synuclein as central to PD pathogenesis.
Testability Score: 10/10 — Seed amplification assays (RT-QuIC, PMCA) detect α-synuclein pathology in CSF and tissue.
Therapeutic Potential Score: 9/10 — Immunotherapies (prasinezumab,运动抗体) in clinical trials; gene therapy approaches in development.
The mitochondrial hypothesis proposes that defects in mitochondrial function, particularly in complex I of the electron transport chain, are central to PD pathogenesis. This is supported by toxin-induced parkinsonism (MPTP, rotenone) and genetic evidence.
Evidence Breakdown:
Confidence Level: Strong — Robust evidence from multiple model systems and human tissue.
Testability Score: 9/10 — Multiple readouts including mitochondrial function assays, imaging, and genetic testing available.
Therapeutic Potential Score: 9/10 — Mitochondrial quality control enhancers in development; coenzyme Q10 and mitophagy modulators being tested.
Protein aggregation spreading: Prion-like propagation — Template-directed misfolding allows pathological proteins to spread through connected neural networks. Documented for Aβ, tau, α-synuclein, TDP-43, and SOD1. [@prion2020]
Network degeneration: Connected circuit vulnerability — Neurodegeneration spreads along anatomically and functionally connected networks. Explains predictable patterns of progression in AD, PD, and FTLD.
Oligomeric toxicity: Soluble aggregates as toxic species — Soluble oligomers of Aβ, tau, and α-synuclein are more toxic than fibrillar plaques/tangles. Targeting oligomers may be more effective than removing plaques.
Glial involvement: Astrocyte and microglia contributions — Glial cells play active roles in disease progression through neuroinflammation, metabolic support, and debris clearance.
| Hypothesis | Model Systems | Readouts | Key References |
|---|---|---|---|
| Amyloid | APP/PS1 mice, iPSC neurons, organoids | Behavior, biochemistry, imaging | [@ Hardy1992] |
| Tau | P301S mice, iPSC-derived neurons, brain organoids | Pathology, behavior, tau PET | [@braak2003] |
| Synuclein | α-syn transgenic mice, iPSC neurons | Pathology, behavior, seeding assays | [@park2014] |
| Neuroinflammation | Mouse models, human iPSC glia | Imaging, cytokine profiling, RNA-seq | [@neuroinf2021] |
| Mitochondrial | C. elegans, drosophila, mouse models, human iPSC | Complex I activity, mitophagy markers | [@mito2023] |
| Hypothesis | Approaches | Biomarkers | Status |
|---|---|---|---|
| Amyloid | PET, CSF, blood | Aβ42, amyloid PET | Validated |
| Tau | PET, CSF, blood | p-tau181, p-tau217, tau PET | Validated |
| Inflammation | PET, CSF, blood | TSPO, cytokines, soluble receptors | Validated |
| Neurodegeneration | MRI, PET, EEG | Connectivity, metabolism, network dynamics | Validated |
| Synuclein | CSF, tissue, skin biopsy | Seed amplification, RT-QuIC | Emerging |
| Target | Disease | Approach | Status | Priority |
|---|---|---|---|---|
| Aβ plaques/tetramers | AD | Antibodies, small molecules | Phase 3-4 | High |
| Tau oligomers/fibrils | AD | Antibodies, inhibitors | Phase 1-2 | High |
| α-synuclein | PD | Antibodies, seeding inhibitors | Phase 1-3 | High |
| TREM2 | AD/PD | Agonists, modulators | Preclinical-Phase 1 | High |
| Mitochondrial quality | PD/AD | Mitophagy enhancers, antioxidants | Phase 2-3 | Medium |
| Neuroinflammation | AD/PD/ALS | Microglial modulators | Phase 1-2 | High |
Several pathogenic mechanisms are common across multiple neurodegenerative diseases:
| Pathway | AD | PD | ALS | FTLD |
|---|---|---|---|---|
| Protein aggregation | Aβ, tau | α-syn | TDP-43, SOD1 | TDP-43, tau |
| Mitochondrial dysfunction | ✓ | ✓++ | ✓ | ✓ |
| Neuroinflammation | ✓++ | ✓++ | ✓++ | ✓+ |
| RNA metabolism | ✓ | ✓ | ✓++ | ✓++ |
| Network failure | ✓++ | ✓+ | ✓+ | ✓+ |
The network degeneration hypothesis proposes that pathological proteins spread along functionally connected neural networks, explaining the characteristic patterns of progression in each disease: